Intellicell Biosciences Inc (fka SVFC)

[stervc]

SVFC & CYTX ** Compare & Contrast…

First, observe below as a study from Merck confirmed that the SVFC (IntelliCell) stem cell process was 10 times greater than Cytori which trades on the NASDAQ under the ticker of CYTX at $2.60+ per share:

http://www.forbes.com/sites/genemarcial/2011/08/28/human-bodys-fat-seen-as-best-source-of-stem-cells-for-regenerative-therapies/
A study of IntelliCell’s technology by Millipore, a division of Merck AG of Germany, confirmed that it produced an average of 10 times the number of SVF cells containing adult adipose stem cells from less than which the company believes is used by any of its present competition that use enzymes in their process. The study also showed that the SVF cells produced by IntelliCell contain all of the viable cells that are manufactured by competing technologies that use enzymes, such as Cytori.

Now let’s compare & contrast SVFC with CYTX…

http://www.cytori.com/Home.aspx


http://www.intellicellbiosciences.com/index.html


CYTX = $2.60+ per share
SVFC = .018+ per share

CYTX Outstanding Shares (OS) = 67,183,050 shares
SVFC Outstanding Shares (OS) = 150,000,000 shares

CYTX Market Cap = $174,675,930 as of currently Aug 8 2013
SVFC Market Cap = $2,700,000 as of currently Aug 8, 2013

Just by considering the above Market Cap Analysis for both SVFC and CYTX, SVFC is 64.69 times cheaper or smaller than where CYTX exists, but yet SVFC’s stem cell process is 10 times better. This means that it could be justified for SVFC to be trading 64.69 times higher than its current price of .018+ per share. That would equate to… $1.16 per share for a value of where SVFC could fundamentally exist to trade; conservatively speaking.

Let’s further analyze why SVFC has a better stem cell process than CYTX.

http://www.thelifesciencesreport.com/pub/na/the-stem-cell-revolution-can-jump-start-your-portfolio-jason-kolbert
…The IntelliCell process, branded IntelliSonics, is similar to the Cytori process in that they both use lipoaspirate. But the IntelliCell process produces a different cellular population because, with its sonification (ultrasound) process, the blood components are not washed out. The stromal vascular fraction of IntelliCell contains the hematopoietic cells. The final product is quality-controlled, checked for any contamination and cell viability is measured. …

Something else that was key to note was that SVFC mentioned that they have completed the preclinical protocols in anticipation expects to begin a clinical trial for osteoarthritis of the knee under an FDA investigational new drug application in mid-2013. An email from the company was recently posted confirming that news is due any day now. This very well could be one of the few of the long awaited PRs expected to be released.

Also important to note is that SVFC provides product today to ReGen Medical while at the same time is building a fantastic database of patient experience that will be used to focus on clinical applications:

http://regenmedicalpc.com/cellular-therapy.php


http://www.victordermatologyandrejuvenation.com/


http://www.stevenvictormd.com/


Bottom line, my point is that if CYTX is trading in the $2.60 per share on the NASDAQ, then SVFC (IntelliCell) should not trading here in the .018s, but definitely somewhere much higher.

v/r
Sterling